

**Supplementary Table 1.** Source, clinical, pathological and molecular features of breast cell lines used in this study

cell lines	Molecular subtypes (1)	Molecular subtypes (this study)	Aldefluor phenotype	ER	PR	ERBB2	source	Histological type	age (years)	culture media	culture conditions	Tumorigenicity	References
184A1	Not tested	Bas	5%-99%	-	-	-	PT	NB		Ham's F12, 5%-IECT	37°C, 5% CO2	Non tumorigenic	B
BrCa-MZ-01	Not tested	Bas	1%-5%	-	-	-	PT	MC	61	RPMI 10%FBS	37°C, 5% CO2	Tumorigenic(10 <sup>6</sup> cells injected s.c)	(2)
BT-20	Ba A	Bas	0%-1%	-	-	-	PT	IDC	74	RPMI, 10% FBS	37°C, 5% CO2	Tumorigenic, (grade II ADK)	B
HCC1500	Ba B	Lu	0%	+	-	-	PT	IDC	32	RPMI, 10% FBS	37°C, 5% CO2	Not tested	B
HCC1806	NA	Bas	1%-5%	-	-	-	PT	IDC		RPMI 10%FBS	37°C, 5% CO2	Non tumorigenic	(3)
HCC1937	Ba A	Bas	1%-5%	-	-	-	PT	IDC	24	RPMI 10%FBS	37°C, 5% CO2	Not tested	
HCC1954	Ba A	NA	1%-5%	-	-	+	PT	IDC	61	RPMI 10%FBS	37°C, 5% CO2	Not tested	
HCC38	Ba B	Bas	100%	-	-	-	PT	IDC	50	RPMI 10%FBS	37°C, 5% CO2	Not tested	
HME1	Not tested	Bas	5%-99%	-	-	-	PT	NB		Ham's F12, SF-IH	37°C, 5% CO2	Non tumorigenic	
Hs578T	Ba B	Mes	0%-1%	-	-	-	PT	IDC	74	DMEM, 10% FBS	37°C, 5% CO2	Non tumorigenic	(4)
MCF10A	Ba B	Bas	0%-1%	-	-	-	PT	FD	36	Ham's F12, 5%-IECT	37°C, 5% CO2	Non tumorigenic	B
MCF7	Lu	Lu	0%-1%	+	+	-	PE	IDC	69	RPMI, 10% FBS	37°C, 5% CO2	Tumorigenic (with estrogen)	(5)
MD-MB-134	Lu	Lu	0%	+	-	-	PE	IDC	47	DMEM, 10% FBS	37°C, 5% CO2	Tumorigenic (10 <sup>8</sup> cells)	(6)
MD-MB-157	Ba B	Mes	1%-5%	-	-	-	PE	MC	44	DMEM, 10% FBS	37°C, 5% CO2	Tumorigenic (10 <sup>8</sup> cells)	(6)
MD-MB-231	Ba B	Mes	0%-1%	-	-	-	PE	AC	51	DMEM, 10% FBS	37°C, 5% CO2	Yes, poorly differentiated ADK	(6)
MD-MB-361	Lu	Lu	0%	+	-	+	PT	AC	40	DMEM, 10%FBS	37°C, 5% CO2	Tumorigenic (10 <sup>8</sup> cells)	(6)
MD-MB-436	Ba B	Bas	1%-5%	-	-	-	PE	IDC	43	DMEM, 10% FBS	37°C, 5% CO2	Non tumorigenic (10 <sup>8</sup> cells)	(6)
MD-MB-453	Lu	Lu	0%-1%	-	-	+	PE	AC	48	DMEM, 10%FBS	37°C, 5% CO2	Non tumorigenic (10 <sup>8</sup> cells)	(7)
S68	Not tested	Lu	1%-5%	-	-	-	P.Br	AC		RPMI 10%FBS	37°C, 5% CO2	Not tested	

cell lines	Molecular subtypes (1)	Molecular subtypes (this study)	Aldefluor phenotype	ER	PR	ERBB2	source	Histological type	age (years)	culture media	culture conditions	Tumorigenicity	Ref
SK-BR-3	Lu	Lu	100%	-	-	+	PE	AC	43	DMEM, 10% FBS	37°C, 5% CO2	Non tumorigenic (10 <sup>8</sup> cells)	(7)
SK-BR-7	Not tested	Mes	5%-99%	-	-	-	PT	Ca		RPMI 10%FBS	37°C, 5% CO2	Not tested	
SUM44	Lu	NA	0%	+	-	-	PE	Ca		Ham's F12, SF-IH	37°C, 5% CO2	Tumourigenic	
SUM52	Lu	Lu	0%	+	-	-	PE	Ca		Ham's F12, SF-IH	37°C, 5% CO2	Not tested	
SUM149	Ba B	Bas	5%-99%	-	-	-	PT	IBC (A)		Ham's F12, 5%-IE	37°C, 5% CO2	Tumourigenic (1.5X10 <sup>6</sup> in m.f.p)	(8)
SUM159	Ba B	Mes	5%-99%	-	-	-	PT	An Ca (A)		Ham's F12, 5%-IH	37°C, 5% CO2	Tumourigenic (10 <sup>8</sup> in m.f.p)	(9)
SUM185	Lu	NA	0%	-	-	+	PE	IDC (A)		Ham's F12, 5%-IH	37°C, 5% CO2	Not tested	
SUM190	Ba A	NA	0%	-	-	+	PT	LABC or IBC (A)		Ham's F12, 5%-IH	37°C, 5% CO2	Not tested	
SUM225	Ba A	Bas	0%-1%	-	-	+	CWN	IDC (A)		Ham's F12, 5%-IH	37°C, 5% CO2	Not tested	
SUM229	ND	NA	1%-5%	-	-	-	PE	Ca (A)		Ham's F12, 5%-IH	37°C, 5% CO2	Not tested	
T-47D	Lu	Lu	0%	+	+	-	PE	IDC	54	RPMI 10%FBS	37°C, 5% CO2	Tumourigenic (with estrogen)	(4)
ZR-75-1	Lu	Lu	0%-1%	+	-	-	AF	IDC	63	RPMI, 10% FBS	37°C, 5% CO2	Tumourigenic (with estrogen)	(4)
ZR-75-30	Lu	Lu	0%	+	-	+	AF	IDC	47	RPMI, 10% FBS	37°C, 5% CO2	Tumourigenic (5-8 X10 <sup>6</sup> cells)	(10)
ZR-75-B	Lu	Lu	0%	+	-	-	AF	IDC		RPMI, 10% FBS	37°C, 5% CO2	Not tested	

A, informations obtained on Asterand website (<http://solutions.asterand.com/Human-Cell-Lines-s/1.htm>); **AC**, adenocarcinoma; **ADK**, adenocarcinoma; **AF**, ascites fluid; **An Ca**, anaplastic carcinoma; **Ba**, Basal; **Ca**, carcinoma; **CWN**, Chest wall nodule; **FD**, fibrocystic disease; **IBC**, inflammatory breast cancer; **IDC**, infiltrating ductal carcinoma; **LABC**, locally advanced breast cancer; **Lu**, Luminal; **MC**, metaplastic carcinoma; **NB**, normal breast; **NA**, not attributed; **ND**, not done; **P. Br**, primary breast; **PE**, pleural effusion; ref, references; **B**, informations obtained on Berkeley lab website (<http://icbp.lbl.gov/breastcancer/celllines.php>)

1. Neve,R.M., Chin,K., Fridlyand,J., Yeh,J., Baehner,F.L., Fevr,T., Clark,L., Bayani,N., Coppe,J.P., Tong,F. *et al.* 2006. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell* **10**:515-527.
2. Mobus,V.J., Moll,R., Gerharz,C.D., Kieback,D.G., Merk,O., Runnebaum,I.B., Linner,S., Dreher,L., Grill,H.J., and Kreienberg,R. 1998. Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin. *Int.J Cancer* **77**:415-423.
3. Gazdar,A.F., Kurvari,V., Virmani,A., Gollahon,L., Sakaguchi,M., Westerfield,M., Kodagoda,D., Stasny,V., Cunningham,H.T., Wistuba,I.I. *et al.* 1998. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. *Int.J Cancer* **78**:766-774.
4. Lacroix,M. and Leclercq,G. 2004. Relevance of breast cancer cell lines as models for breast tumours: an update. *Breast Cancer Res.Treat.* **83**:249-289.
5. Osborne,C.K., Hobbs,K., and Trent,J.M. 1987. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. *Breast Cancer Res.Treat.* **9**:111-121.
6. Cailleau,R., Olive,M., and Cruciger,Q.V. 1978. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. *In Vitro* **14**:911-915.
7. Giovanella,B.C., Vardeman,D.M., Williams,L.J., Taylor,D.J., de Ipolyi,P.D., Greeff,P.J., Stehlin,J.S., Ullrich,A., Cailleau,R., Slamon,D.J. *et al.* 1991. Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene. *Int.J Cancer* **47**:66-71.
8. van Golen,K.L., Wu,Z.F., Qiao,X.T., Bao,L.W., and Merajver,S.D. 2000. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. *Cancer Res.* **60**:5832-5838.
9. Flanagan,L., Van Weelden,K., Ammerman,C., Ethier,S.P., and Welsh,J. 1999. SUM-159PT cells: a novel estrogen independent human breast cancer model system. *Breast Cancer Res.Treat.* **58**:193-204.
10. Blumenthal,R.D., Waskewich,C., Goldenberg,D.M., Lew,W., Fiefluh,C., and Burton,J. 2001. Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. *Clin.Cancer Res.* **7**:3178-3185.